Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene‐dosage regulated candidate genes

Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation and several other cytogenetic aberrations, including heterozygous loss of chromosomal arms 1p, 6q, 11q and 13q and/or gains of 3q and 8q. The common intervals of chromosomal imbalance have been narrowed down using array‐comparative genomic hybridization (CGH). However, the chromosomal intervals still contain many genes potentially involved in MCL pathogeny. Combined analysis of tiling‐resolution array‐CGH with gene expression profiling on 11 MCL tumours enabled the identification of genomic alterations and their corresponding gene expression profiles. Only subsets of genes located within given cytogenetic anomaly‐intervals showed a concomitant change in mRNA expression level. The genes that showed consistent correlation between DNA copy number and RNA expression levels are likely to be important in MCL pathology. Besides several ‘anonymous genes’, we also identified various fully annotated genes, whose gene products are involved in cyclic adenosine monophosphate‐regulated pathways (PRKACB), DNA damage repair, maintenance of chromosome stability and prevention of rereplication (ATM, ERCC5, FBXO5), energy metabolism (such as genes that are involved in the synthesis of proteins encoded by the mitochondrial genome) and signal transduction (ARHGAP29). Deregulation of these gene products may interfere with the signalling pathways that are involved in MCL tumour development and maintenance.

[1]  Hugo Naya,et al.  Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis , 2008, Leukemia.

[2]  C. Croce,et al.  MicroRNAs in the pathogeny of chronic lymphocytic leukaemia , 2007, British journal of haematology.

[3]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[4]  R. Wieser.  The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. , 2007, Gene.

[5]  J. Pines,et al.  Emi1 is needed to couple DNA replication with mitosis but does not regulate activation of the mitotic APC/C , 2007, The Journal of cell biology.

[6]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Steinemann,et al.  Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas. , 2007, Haematologica.

[8]  Anindya Dutta,et al.  APC/C – the master controller of origin licensing? , 2007, Cell Division.

[9]  Anindya Dutta,et al.  The APC/C inhibitor, Emi1, is essential for prevention of rereplication. , 2007, Genes & development.

[10]  E. Campo,et al.  Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability , 2006, International journal of cancer.

[11]  Cheng Li,et al.  Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.

[12]  Tara L. Naylor,et al.  microRNAs exhibit high frequency genomic alterations in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Tanabe,et al.  Role of mitochondria as the gardens of cell death , 2006, Cancer Chemotherapy and Pharmacology.

[14]  C. Thompson,et al.  Akt-dependent transformation: there is more to growth than just surviving , 2005, Oncogene.

[15]  D. Pinkel,et al.  Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. , 2005, Blood.

[16]  K. Kariya,et al.  PARG1, a protein-tyrosine phosphatase-associated RhoGAP, as a putative Rap2 effector. , 2005, Biochemical and biophysical research communications.

[17]  Wayne Tam,et al.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[19]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[20]  Rolph Pfundt,et al.  Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. , 2005, Blood.

[21]  Ramón Díaz-Uriarte,et al.  Identification of amplified and highly expressed genes in amplicons of the T-cell line huT78 detected by cDNA microarray CGH , 2005, Molecular Cancer.

[22]  Randy D Gascoyne,et al.  Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. , 2004, Human molecular genetics.

[23]  J. Pelkonen,et al.  Mechanisms of B cell receptor induced apoptosis , 2004, Apoptosis.

[24]  G. Ott,et al.  Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. , 2004, Blood.

[25]  R. Ren,et al.  Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice , 2004, Oncogene.

[26]  Nerea Martínez,et al.  The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. , 2003, Cancer research.

[27]  S. de Vos,et al.  Cell Cycle Alterations in the Blastoid Variant of Mantle Cell Lymphoma (MCL-BV) as Detected by Gene Expression Profiling of Mantle Cell Lymphoma (MCL) and MCL-BV , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[28]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[29]  T. Yao,et al.  Regulation of E2A Activities by Histone Acetyltransferases in B Lymphocyte Development* , 2003, The Journal of Biological Chemistry.

[30]  J. Herman,et al.  CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. , 2002, Blood.

[31]  J. Kere,et al.  Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma , 2002, British journal of haematology.

[32]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Thompson,et al.  Cell metabolism in the regulation of programmed cell death , 2002, Trends in Endocrinology & Metabolism.

[34]  R. Siebert,et al.  Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. , 2001, Blood.

[35]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[36]  Cheng Li,et al.  Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application , 2001, Genome Biology.

[37]  S. de Vos,et al.  Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. , 2001, Blood.

[38]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Taskén,et al.  Specificity in the cAMP/PKA signaling pathway. differential expression, regulation, and subcellular localization of subunits of PKA. , 2000, Frontiers in bioscience : a journal and virtual library.

[40]  H. Döhner,et al.  Mantle cell lymphoma is characterized by inactivation of the ATM gene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. James,et al.  Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. , 1999, Blood.

[42]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.

[43]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[44]  F. Bosch,et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.

[45]  H. Lovec,et al.  Cyclin D1/bcl‐1 cooperates with myc genes in the generation of B‐cell lymphoma in transgenic mice. , 1994, The EMBO journal.

[46]  J.M. Adams,et al.  Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. , 1994, The EMBO journal.

[47]  Michael B. Yaffe,et al.  TCP1 complex is a molecular chaperone in tubulin biogenesis , 1992, Nature.

[48]  P. Nowell,et al.  Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11 ; 14) chromosome translocation , 1985, Nature.

[49]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[50]  P. Nowell,et al.  The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Juan F. García,et al.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.

[52]  Borja Saez,et al.  Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. , 2006, Haematologica.

[53]  R. Rosenquist,et al.  Immunoglobulin gene analysis of mature B-cell malignancies , 2005, Medical oncology.

[54]  A. Rosenwald,et al.  Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms , 2005, Leukemia.

[55]  J. Herman,et al.  CHK 2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas , 2002 .

[56]  F. Bosch,et al.  ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. , 2002, Blood.

[57]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[58]  A. López-Guillermo,et al.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. , 1994, Blood.